Addendum to Commission A12-02 (Rilpivirine / Emtricitabine / Tenofovir) [Internet].

The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 [HIV-1] infection in antiretroviral-naïve adult patients with a viral load of ≤ 100,000 HIV-1 RNA copies/mL).

http://ift.tt/2t1INtJ